Denaverine
Structural formula | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|
General | ||||||||||
Non-proprietary name | Denaverine | |||||||||
other names |
2- (dimethylamino) ethyl (2-ethylbutoxy) diphenylacetic acid |
|||||||||
Molecular formula | C 24 H 33 NO 3 | |||||||||
External identifiers / databases | ||||||||||
|
||||||||||
Drug information | ||||||||||
ATC code | ||||||||||
Drug class | ||||||||||
properties | ||||||||||
Molar mass | 383.52 g mol −1 | |||||||||
safety instructions | ||||||||||
|
||||||||||
As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions . |
Denaverine is a drug , which as neurotropic - musculotropic anticonvulsant is used d. that is, it works at both the nerve and muscle fiber levels.
Denaverine was patented in 1974 for VEB Arzneimittelwerk Dresden and was marketed as Spasmalgan ® ( APOGEPHA Arzneimittel GmbH, Dresden).
literature
- Roche Lexicon Medicine (5th ed.). Urban & Fischer, 2003.
Individual evidence
- ↑ This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.